Uncertainty surrounding Bedrocan threatens the supply of medical cannabis flowers to Danish patients
The Bedrocan's difficulties in the Netherlands could have consequences beyond the Netherlands' borders. In Denmark, Stenocare now warns that there could be a disruption in the supply of Bedrocan medical cannabis products starting in 2027, as a direct result of changes to the Dutch export system.
The Danish company, which markets certain Bedrocan products under the brand name CannGros, says it is working with the authorities and exploring alternative solutions to prevent disruptions for patients.
The Planned End of Exports Through the WTO
Since 2003, Dutch production of medical marijuana The supply chain for the official system is based on a specific organizational structure. Bedrocan cultivates the products, while the’Office of Medicinal Cannabis (OMC), which operates under the authority of the Dutch Ministry of Health, serves as an official supplier, particularly for exports to several European countries.
However, this mechanism must be eliminated. According to Stenocare, the WTO plans to end international exports of medical cannabis by the end of 2026.
This change had been in the works since 2024, but its timeline has already been pushed back several times to give the Dutch legislature time to amend its Opium Act, which governs these cannabis-related activities.
The problem now lies in the mismatch between the two timelines. The current export channel must close before the new framework allowing Bedrocan to supply its international customers directly becomes operational. The year 2027 could therefore become a particularly challenging transition period.
This uncertainty comes at a time when Bedrocan Nederland B.V. and Bedrocan International B.V. have been placed under a suspension of payments supervised by the Dutch courts. This situation follows directly from the’the expiration of the previous supply agreement concluded with the WTO and the accumulated delays in legislative reform.
The problem thus goes beyond the producer's financial situation alone and also concerns the continuity of certain European distribution channels for medical marijuana.
Stenocare is looking for alternatives for Danish patients
Visit Denmark, the products in question are marketed by Stenocare under the brand name CannGros. Another Danish supplier also sells Bedrocan products under a different brand name. Both companies therefore face the same risk regarding their supply starting in 2027.
For now, Stenocare says that CannGros products will continue to be distributed on the Danish market for the remainder of 2026.
At the same time, the company says it is in discussions with Danish and Dutch authorities to identify potential transitional solutions for 2027. It is also working to establish alternative supply chains and identify products that could replace the Bedrocan portfolio if necessary.
The Stenocare Medical Cannabis Oils are not, however, affected by this situation, either in Denmark or in the company’s other markets.
-
Business4 weeks ago
Cronos Completes the Acquisition of CanAdelaar for 57.5 million euros
-
Cannabis in Quebec3 weeks ago
Cannabis: What France Could Learn from Quebec, Eight Years After Legalization
-
Cannabis in New Zealand3 weeks ago
Chronic Pain: New Zealand Is Testing Cannabis to Improve Sleep
-
Cannabis in France4 weeks ago
Dr. Pascal Douek, a tireless advocate for medical cannabis in France, has died
-
Cannabis in France3 weeks ago
Medical cannabis: The Greens introduce two amendments to accelerate its widespread adoption
-
Cannabis in Canada3 weeks ago
A Canadian study reveals the pleasant psychotropic effects of high-dose CBD
-
Studies on cannabis3 weeks ago
More THC, barely any additional effects: A new study challenges common assumptions about the potency of cannabis
-
Cannabis in Argentina3 weeks ago
The Argentine province of Chubut is creating its own framework for medical cannabis


You must be logged in to post a comment Login